RT Journal Article
T1 Cancer chemotherapy resistance: Mechanisms and recent breakthrough in targeted drug delivery
A1 Davodabadi, Fatemeh
A1 Sajjadi, Seyedeh Fatemeh
A1 Sarhadi, Mohammad
A1 Mirghasemi, Shaghayegh
A1 Hezaveh, Mahdieh Nadali
A1 Khosravi, Samin
A1 Andani, Mahdieh Kamali
A1 Cordani, Marco
A1 Basiri, Mohsen
A1 Ghavami, Saeid
AB Conventional chemotherapy, one of the most widely used cancer treatment methods, has serious side effects, and usually results in cancer treatment failure. Drug resistance is one of the primary reasons for this failure. The most significant drawbacks of systemic chemotherapy are rapid clearance from the circulation, the drug's low concentration in the tumor site, and considerable adverse effects outside the tumor. Several ways have been developed to boost neoplasm treatment efficacy and overcome medication resistance. In recent years, targeted drug delivery has become an essential therapeutic application. As more mechanisms of tumor treatment resistance are discovered, nanoparticles (NPs) are designed to target these pathways. Therefore, understanding the limitations and challenges of this technology is critical for nanocarrier evaluation. Nano-drugs have been increasingly employed in medicine, incorporating therapeutic applications for more precise and effective tumor diagnosis, therapy, and targeting. Many benefits of NP-based drug delivery systems in cancer treatment have been proven, including good pharmacokinetics, tumor cell-specific targeting, decreased side effects, and lessened drug resistance. As more mechanisms of tumor treatment resistance are discovered, NPs are designed to target these pathways. At the moment, this innovative technology has the potential to bring fresh insights into cancer therapy. Therefore, understanding the limitations and challenges of this technology is critical for nanocarrier evaluation.
PB Elsevier
SN 0014-2999
YR 2023
FD 2023-08-24
LK https://hdl.handle.net/20.500.14352/87990
UL https://hdl.handle.net/20.500.14352/87990
LA eng
NO Ministerio de Ciencia e Innovación (MICIN)
NO Agencia Estatal de Investigación
NO Unión Europea
NO Universidad Complutense de Madrid
DS Docta Complutense
RD 8 abr 2025